Literature DB >> 24430776

Beyond the dichotomy: a tool for distinguishing between experimental, innovative and established treatment.

Veerle Provoost1, Kelly Tilleman, Arianna D'Angelo, Petra De Sutter, Guido de Wert, Willianne Nelen, Guido Pennings, Francoise Shenfield, Wybo Dondorp.   

Abstract

STUDY QUESTION: The precise delineation of the research phase is a recurrent subject of debate: When is the evidence base firm enough to decide that a new technology or treatment no longer needs to be regarded as 'experimental'? SUMMARY ANSWER: We propose a framework that distinguishes between three instead of two types of treatment and describes a continuum from experimental over innovative to established treatment, offering a tool meant to facilitate decision-making about the introduction of new technologies in the clinic. WHAT IS KNOWN ALREADY: Traditionally, guidelines from medical societies on the notion of 'experimental treatment' depart from a dichotomy between experimental and established treatment. However, in the field of reproductive medicine, there are several problems with a dichotomous framework. First, it does not offer an adequate account of the reality in the clinic. Secondly, this view may bring about several negative effects for the patient, such as techniques being considered established too early, holding risks unknown to patients. A further drawback of the dichotomy is that if a technique is no longer considered experimental, centres offering the technique may no longer consider it useful gathering and critically examining (follow-up) data. STUDY DESIGN, SIZE, DURATION: The framework and scoring tool were developed over several phases during which the authors operated as a consensus group of experts. PARTICIPANTS/MATERIALS, SETTING,
METHODS: The scoring tool reflects the continuous progression of a new procedure from experimental through innovative to established. For this evolution, four criteria were considered relevant. The first (efficacy) is a categorical criterion (pass/fail). The other three criteria (safety, procedural reliability and transparency and effectiveness) are ordinal in nature. Thresholds have been introduced for all four criteria to avoid that a technology scoring high on procedure and effectiveness but extremely low on safety could move to the next level because of a sufficiently high overall score. MAIN RESULTS AND THE ROLE OF CHANCE: Only treatments that are rated above the thresholds for all four criteria could be considered at least innovative treatments. When they score 4 or higher on the last three criteria, they are considered established treatments. LIMITATIONS, REASONS FOR CAUTION: Knowledge about the procedures or techniques under discussion is essential in order to use the tool. WIDER IMPLICATIONS OF THE
FINDINGS: The tool is designed to be used on a macro-level (e.g. by professional societies) although it could also be valuable in the local setting. Both the framework and the tool can bring more clarity on the notion of 'experimental treatment', especially with regard to how to decide when a specific technology or treatment falls in this category and when it can move into one of the other categories. STUDY FUNDING/COMPETING INTEREST(S): none. TRIAL REGISTRATION NUMBER: none.

Entities:  

Keywords:  follow-up studies; investigational therapies; patient safety; reproductive medicine; research ethics committees

Mesh:

Year:  2014        PMID: 24430776     DOI: 10.1093/humrep/det463

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  11 in total

1.  Fertility preservation issues in pediatric hematopoietic stem cell transplantation: practical approaches from the consensus of the Pediatric Diseases Working Party of the EBMT and the International BFM Study Group.

Authors:  A Balduzzi; J-H Dalle; K Jahnukainen; M von Wolff; G Lucchini; M Ifversen; K T Macklon; C Poirot; T Diesch; A Jarisch; D Bresters; I Yaniv; B Gibson; A M Willasch; R Fadini; L Ferrari; A Lawitschka; A Ahler; N Sänger; S Corbacioglu; M Ansari; R Moffat; A Dalissier; E Beohou; P Sedlacek; A Lankester; C D De Heredia Rubio; K Vettenranta; J Wachowiak; A Yesilipek; E Trigoso; T Klingebiel; C Peters; P Bader
Journal:  Bone Marrow Transplant       Date:  2017-07-24       Impact factor: 5.483

2.  Oocyte cryopreservation beyond cancer: tools for ethical reflection.

Authors:  Alma Linkeviciute; Fedro A Peccatori; Virginia Sanchini; Giovanni Boniolo
Journal:  J Assist Reprod Genet       Date:  2015-07-03       Impact factor: 3.412

3.  Enucleated oocyte donation: first for infertility treatment, then for mitochondrial diseases.

Authors:  Guido Pennings
Journal:  J Assist Reprod Genet       Date:  2022-02-07       Impact factor: 3.412

4.  The path toward ectogenesis: looking beyond the technical challenges.

Authors:  Seppe Segers
Journal:  BMC Med Ethics       Date:  2021-05-13       Impact factor: 2.652

5.  Fertility preservation in boys: recent developments and new insights .

Authors:  E Goossens; K Jahnukainen; R T Mitchell; Amm van Pelt; G Pennings; N Rives; J Poels; C Wyns; S Lane; K A Rodriguez-Wallberg; A Rives; H Valli-Pulaski; S Steimer; S Kliesch; A Braye; M M Andres; J Medrano; L Ramos; S G Kristensen; C Y Andersen; R Bjarnason; K E Orwig; N Neuhaus; J B Stukenborg
Journal:  Hum Reprod Open       Date:  2020-06-06

6.  ESHRE certification of ART centres for good laboratory and clinical practice.

Authors:  Luca Gianaroli; Anna Veiga; Stephan Gordts; Thomas Ebner; Bryan Woodward; Catherine Plas; Wil van Groesen; Serena Sgargi; Borut Kovačič
Journal:  Hum Reprod Open       Date:  2022-09-14

7.  Repetitive Maturation of Oocytes From Non-Stimulated Xenografted Ovarian Tissue From a Prepubertal Patient Indicating the Independence of Human Ovarian Tissue.

Authors:  Nathalie Raffel; Laura Lotz; Inge Hoffmann; Jana Liebenthron; Stephan Söder; Matthias W Beckmann; Ralf Dittrich
Journal:  Geburtshilfe Frauenheilkd       Date:  2017-12-18       Impact factor: 2.915

8.  Balancing animal welfare and assisted reproduction: ethics of preclinical animal research for testing new reproductive technologies.

Authors:  Verna Jans; Wybo Dondorp; Ellen Goossens; Heidi Mertes; Guido Pennings; Guido de Wert
Journal:  Med Health Care Philos       Date:  2018-12

Review 9.  Time-lapse technology for embryo culture and selection.

Authors:  Kersti Lundin; Hannah Park
Journal:  Ups J Med Sci       Date:  2020-02-25       Impact factor: 2.384

10.  Fetoscopic myelomeningocoele closure: Is the scientific evidence enough to challenge the gold standard for prenatal surgery?

Authors:  E Joanne Verweij; Martine C de Vries; Esther J Oldekamp; Alex J Eggink; Dick Oepkes; Femke Slaghekke; Jochem K H Spoor; Jan A Deprest; Jena L Miller; Ahmet A Baschat; Philip L J DeKoninck
Journal:  Prenat Diagn       Date:  2021-04-05       Impact factor: 3.050

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.